ACT Initiates Treatment of Higher-Dosage Cohort in Clinical Trials...

Advanced Cell Technology, Inc. , a leader in the field of regenerative medicine, today announced treatment of patients in the third patient cohort, in each of its two U.S. clinical trials for forms of macular degeneration.

http://www.businesswire.com/news/topix/20130401005341/en